These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1510386)

  • 41. Neuronal vulnerability in Parkinson's disease.
    Double KL
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
    Hill WD; Arai M; Cohen JA; Trojanowski JQ
    J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.
    Floor E
    Cell Mol Biol (Noisy-le-grand); 2000 Jun; 46(4):709-20. PubMed ID: 10875434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.
    Dijkstra AA; Voorn P; Berendse HW; Groenewegen HJ; ; Rozemuller AJ; van de Berg WD
    Mov Disord; 2014 Sep; 29(10):1244-51. PubMed ID: 24996051
    [TBL] [Abstract][Full Text] [Related]  

  • 46. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease.
    Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP
    Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
    Counihan TJ; Penney JB
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it.
    Fahn S; Cohen G
    Ann Neurol; 1992 Dec; 32(6):804-12. PubMed ID: 1471873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases.
    Gu M; Owen AD; Toffa SE; Cooper JM; Dexter DT; Jenner P; Marsden CD; Schapira AH
    J Neurol Sci; 1998 Jun; 158(1):24-9. PubMed ID: 9667773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oxidative stress and Parkinson's disease.
    Owen AD; Schapira AH; Jenner P; Marsden CD
    Ann N Y Acad Sci; 1996 Jun; 786():217-23. PubMed ID: 8687021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathogenesis of nigral cell death in Parkinson's disease.
    Przedborski S
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.
    Knörle R
    Neurotox Res; 2018 Feb; 33(2):515-522. PubMed ID: 28879408
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions.
    Elstner M; Müller SK; Leidolt L; Laub C; Krieg L; Schlaudraff F; Liss B; Morris C; Turnbull DM; Masliah E; Prokisch H; Klopstock T; Bender A
    Mol Brain; 2011 Dec; 4():43. PubMed ID: 22188897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. XANES spectroscopy of a single neuron from a patient with Parkinson's disease.
    Yoshida S; Ektessabi A; Fujisawa S
    J Synchrotron Radiat; 2001 Mar; 8(Pt 2):998-1000. PubMed ID: 11513007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Oxidative stress and the brain].
    Tanaka M
    Nihon Ronen Igakkai Zasshi; 1997 Sep; 34(9):706-10. PubMed ID: 9430979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
    Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Iron homeostasis and Parkinson's disease].
    Faucheux BA; Hirsch EC
    Ann Biol Clin (Paris); 1998 Jul; 56 Spec No():23-30. PubMed ID: 9827211
    [No Abstract]   [Full Text] [Related]  

  • 59. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of neuronal iron deposits in Parkinson's disease brain tissue by synchrotron x-ray spectromicroscopy.
    Brooks J; Everett J; Lermyte F; Tjendana Tjhin V; Sadler PJ; Telling N; Collingwood JF
    J Trace Elem Med Biol; 2020 Dec; 62():126555. PubMed ID: 32526631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.